Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Recursion Pharmaceuticals's price to sales ratio was 35.0× on Nov 11, 2026, against 52.1× a year earlier. Over the last 5 years it ranged from 21.7× to 279.5×, with a median of 39.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 35.0× | −11.1 |
| 2025 | Dec 31, 2025 | 46.0× | +16.4 |
| 2024 | Dec 31, 2024 | 29.7× | −15.4 |
| 2023 | Dec 29, 2023 | 45.0× | −1.7 |
| 2022 | Dec 30, 2022 | 46.8× | −232.7 |
| 2021 | Dec 31, 2021 | 279.5× | – |
See a number that looks wrong?